Posted by Michael Wonder on 30 Aug 2021
UCB announces Briviact (brivaracetam) now FDA approved to treat partial-onset seizures in paediatric patients one month of age and older
30 August 2021 - Tablets, oral solution and intravenous dosage forms of Briviact (brivaracetam) now FDA approved as both monotherapy or adjunctive therapy for the treatment of partial-onset seizures in patients one month of age and older.
UCB announced today that the U.S. FDA has approved an expanded indication for Briviact (brivaracetam) CV tablets, oral solution, and injection to treat partial onset seizures in patients as young as one month of age.
